CytoDyn and NIH of Mexico Complete Memorandum of Understanding to Conduct Small Covid-19 Phase 3 Trial for Severe and Critically Ill Patients Jun 29, 2020 6:00am EDT
CytoDyn Initiates Phase 2 Clinical Trial With Leronlimab for Treatment of NASH Jun 11, 2020 6:59pm EDT
CytoDyn Reached Its Enrollment Target for Phase 2 COVID-19 Trial for Mild to Moderate Indication – Primary End Point Announcement Is Next Jun 11, 2020 4:05pm EDT
Drs. Pourhassan and Kelly of CytoDyn to Hold Conference Call to Provide Updates on COVID-19 Phase 2 and 3 Trials, NASH, BLA for HIV and Manufacturing of Leronlimab in 2020-2021 Jun 09, 2020 6:00am EDT
CytoDyn to Present at Wall Street Reporter’s Livestream Event on June 2, 2020 at 12:30 pm ET / 9:30 am PT Jun 01, 2020 6:15am EDT
CytoDyn to Hold Conference Call to Provide Updates on COVID-19 (Phase 2, 3 & eIND), Cancer (mTNBC, Phase 2 for 22 Solid Tumor Cancers), HIV (BLA, Monotherapy), NASH, GvHD and MS May 22, 2020 8:49pm EDT
CytoDyn and the Mexican National Institutes of Health Participate in a Collaborative Study of Leronlimab for the Treatment of Severe/Critical COVID-19 Population May 19, 2020 6:00am EDT
CytoDyn to Prepare a Phase 3 Protocol to Submit to the FDA for a Three-Arm Comparative and Combination Trial of Leronlimab and Remdesivir May 18, 2020 6:00am EDT
